FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or BBusiness Wire • 03/28/25
siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 TrialsGlobeNewsWire • 03/28/25
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades StockBenzinga • 03/24/25
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?Zacks Investment Research • 03/24/25
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in CardiomyopathyZacks Investment Research • 03/21/25
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBioInvestors Business Daily • 03/21/25
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock JumpsBenzinga • 03/21/25
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Business Wire • 03/20/25
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?Zacks Investment Research • 03/14/25
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry LuminaryBusiness Wire • 03/05/25
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D DayBusiness Wire • 02/25/25
Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/13/25
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period ProgressBusiness Wire • 02/13/25
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/10/25